Toward a cure for sickle cell disease
Failed to add items
Add to Cart failed.
Add to Wish List failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
Transformative therapies for sickle cell disease are redefining what is possible for patients, offering the potential for cure alongside substantial risks. In CMAJ, the article Transformative therapies for sickle cell disease outlines how stem cell transplant and emerging gene therapies are changing the trajectory of a condition long defined by recurrent crises, shortened life expectancy, and inequities in care.
Dr. Kareem Jamani, a haematologist and clinical associate professor at the University of Calgary, explains how stem cell transplant replaces a patient’s blood-forming system to eliminate sickling haemoglobin, offering what can reasonably be considered a cure. Outcomes are generally favourable, particularly with matched sibling donors, but risks remain, including graft-versus-host disease, infertility, rejection, and mortality that can reach 5–7% with less well-matched donors. He also outlines the role of gene therapy, which modifies a patient’s own stem cells to increase fetal haemoglobin production, resulting in a functional cure with similar improvements in quality of life.
The episode is grounded in the experience of Ufuoma Muwhen, who underwent a stem cell transplant as a teenager after years of frequent hospitalizations and functional limitations. She describes the toll of both the disease and the treatment process, as well as the shift in her daily life following transplant, including her ability to travel, exercise, and live without recurrent crises. Her account highlights the importance of wraparound supports and trust in the healthcare system.
For physicians, these therapies require balancing meaningful benefit against real risk, often early in life and under uncertainty. The discussion also underscores persistent inequities, including delayed acute care, limited access to fertility preservation, and the challenges of delivering advanced therapies within systems designed around oncology rather than chronic genetic disease.
For more information from our sponsor, go to medicuspensionplan.com
Comments or questions? Text us.
Join us as we explore medical solutions that address the urgent need to change healthcare. Reach out to us about this or any episode you hear. Or tell us about something you'd like to hear on the leading Canadian medical podcast.
You can find Blair and Mojola on X @BlairBigham and @Drmojolaomole
X (in English): @CMAJ
X (en français): @JAMC
Facebook
Instagram: @CMAJ.ca
The CMAJ Podcast is produced by PodCraft Productions